Articles tagged "IMPDH Inhibitor"

2018 American Transplant Congress
Effects of the Addition of Mycophenolate Mofetil on Renal Outcomes in Liver Transplant Recipients: A Single Center Review
M. Henry, M. Vacha.
Nebraska Medicine, Omaha, NE.
Purpose: To evaluate the use of mycophenolate mofetil (MMF) and its effects on renal outcomes in liver transplant recipientsMethods: Adult liver transplant recipients from September…
2016 American Transplant Congress
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.
H. Ishida,¹ K. Tanabe,¹ S. Takahara,² N. Amada,³ K. Takahashi,⁴ H. Toma.⁵
¹Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan; ²Advanced Technology for Transplantation, Osaka University, Osaka, Japan; ³Surgery, JCHO Sendai Hospital, Sendai, Japan; ⁴Niigata Organ Transplant Foundation, Niigata, Japan; ⁵Urology, Toda Chuo Hospital, Toda, Saitama, Japan.
PURPOSE: To compare the clinical outcomes of mizoribine (MZR; 12 mg/kg/day) and mycophenolate mofetil (MMF; 2000 mg/day) in combination with tacrolimus (FK), basiliximab (SIM), and…
2015 American Transplant Congress
Intra-Lymphocyte Concentrations of Mycophenolic Acid Correlate With the Incidence of Early Graft Rejection in Renal Transplant Recipients
Z. Md Dom,² J. Coller,² R. Carroll,³ A. Somogyi,² B. Sallustio.¹
¹Clinical Pharmacology, The Queen Elizabeth Hospital, Adelaide, Australia; ²Discipline of Pharmacology, Univeristy of Adelaide, Adelaide, Australia; ³Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia.
Introduction: Although routine therapeutic drug monitoring of mycophenolic acid (MPA) concentrations in plasma has been recommended to individualize MPA doses in transplant recipients, little is…